U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H9N3O
Molecular Weight 151.1659
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-N-ACETYL-AMIFAMPRIDINE

SMILES

CC(=O)NC1=CN=CC=C1N

InChI

InChIKey=MKZXMKBJWHAKIX-UHFFFAOYSA-N
InChI=1S/C7H9N3O/c1-5(11)10-7-4-9-3-2-6(7)8/h2-4H,1H3,(H2,8,9)(H,10,11)

HIDE SMILES / InChI

Molecular Formula C7H9N3O
Molecular Weight 151.1659
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 15:18:28 GMT 2023
Edited
by admin
on Sat Dec 16 15:18:28 GMT 2023
Record UNII
21G4M49F34
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
3-N-ACETYL-AMIFAMPRIDINE
Common Name English
AMIFAMPRIDINE METABOLITE (3-N-ACETYL-AMIFAMPRIDINE)
Common Name English
ACETAMIDE, N-(4-AMINO-3-PYRIDINYL)-
Systematic Name English
N-(4-AMINO-3-PYRIDINYL)ACETAMIDE
Systematic Name English
Code System Code Type Description
CAS
750570-35-5
Created by admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
PRIMARY
PUBCHEM
11593462
Created by admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
PRIMARY
FDA UNII
21G4M49F34
Created by admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
Related Record Type Details
PARENT -> METABOLITE INACTIVE
Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of AMIFAMPRIDINE metabolism. Poor metabolizers, also referred to as “slow acetylators” (i.e., carriers of two reduced function alleles), have 3.5-to 4.5-fold higher Cmax, and 5.6-to 9fold higher AUC than normal metabolizers, also referred to as “fast/rapid acetylators” (i.e., carriers of two normal function alleles). In the general population, the NAT2 poor metabolizer phenotype prevalence is 40–60% in the White and African American populations, and in 10–30% in Asian ethnic populations (individuals of Japanese, Chinese, or Korean descent).
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC